Clinical Trial Update: Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women [Phase 2]

View source ↗

Summary

Phase 2 safety and reactogenicity results for GSK's investigational RSV vaccine (GSK3003891A) in healthy women have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine (GSK3003891A) (GSK3003891A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED | Results posted: 2017-07-11